PMDA recorded 989 medical-device approvals in FY2024, showing the scale of Japan’s active regulatory system. However, foreign manufacturers cannot treat medical device registration in Japan as a simple filing exercise. They must align JMDN classification, the correct approval route, local MAH responsibilities, and QMS requirements under the PMD Act. Therefore, early regulatory planning can reduce avoidable delays and support a smoother path to market.
Table of Contents
What Is Medical Device Registration in Japan?
Medical device registration in Japan follows the Pharmaceutical and Medical Device Act, or PMD Act. Before legal marketing, manufacturers must identify the device classification and correct regulatory route. Depending on risk level and product type, the device may require notification, third-party certification, or formal approval. Therefore, accurate classification is essential because it determines the review process, evidence requirements, and market-entry pathway.
Why the Correct Japan Registration Pathway Matters?
Choosing the correct Japan registration pathway helps prevent avoidable regulatory delays. An incorrect JMDN code, device class, certification route, MAH structure, or QMS status can trigger extra questions and document requests. Therefore, manufacturers should confirm these elements early. Accurate planning reduces rework, supports smoother PMDA interactions, and helps keep approval timelines under control.
This infographic shows how Japan’s medical device approval pathway changes from Class I to Class IV and why correct classification matters.
Four Regulatory Decisions to Confirm Before Your Japan Submission
A successful Japan submission starts with several regulatory decisions before document preparation begins. First, manufacturers must confirm the correct JMDN code and device class. They should also select the appropriate Todokede, Ninsho, or Shonin route. In addition, the MAH structure and foreign manufacturer responsibilities must be clear. Finally, early QMS planning under Ordinance 169 can reduce rework and prevent avoidable approval delays.
These four regulatory decisions should be confirmed early to build the correct pathway for medical device registration in Japan.
- Confirm the JMDN Code and Device Class (PDF)
- Choose Between Todokede, Ninsho, and Shonin (PDF)
- Set Up the MAH and Foreign Manufacturing Structure (PDF)
- Prepare the QMS for Ordinance 169 Requirements (PDF)
Confirm the JMDN Code and Device Class (PDF)
The JMDN list helps identify the correct device code, definition, and class. It supports accurate pathway selection.
Choose Between Todokede, Ninsho, and Shonin (PDF)
Japan uses different routes based on device risk and eligibility. The correct route may be notification, certification, or approval.
Download Regulatory Updates on Medical Devices in Japan Here
Set Up the MAH and Foreign Manufacturing Structure (PDF)
Foreign manufacturers need the correct MAH and site-registration structure. This supports legal marketing and regulatory responsibility in Japan.
Download Manufacturing and Marketing Procedures for Medical Devices Here
Prepare the QMS for Ordinance 169 Requirements (PDF)
Ordinance 169 defines Japan’s medical device QMS expectations. It also adds Japan-specific requirements beyond ISO 13485.
Download Correspondence between ISO13485:2016 and MHLW MO 169 Chapter 2, as revised in 2021 Here
What Documents Should Foreign Manufacturers Prepare
Foreign manufacturers should prepare a clear regulatory and technical file before starting the Japan submission process. Key documents usually support device classification, product specifications, safety and performance evidence, manufacturing-site details, and QMS compliance. In addition, the file must match the selected Todokede, Ninsho, or Shonin pathway. Therefore, complete and consistent documentation helps reduce regulatory questions and supports a smoother PMDA or certification review.
This infographic highlights the essential documents foreign manufacturers should prepare to support a smooth Japan medical device registration process.
How Long Does PMDA Medical Device Approval Take?
PMDA medical device approval timelines depend on the application category and supporting evidence. New devices generally require the longest review, while generic devices may follow a shorter process. However, additional questions, QMS issues, or applicant response time can extend the overall schedule. Therefore, manufacturers should confirm the correct application category before setting a Japan market-entry timeline.
The table below compares four key PMDA application categories and their approximate approval periods.
| Japan Regulatory Route | Typical Device/Application | Published Timing | Key Point |
|---|---|---|---|
|
Todokede — Notification |
Mainly Class I devices |
No PMDA approval timeline |
Notification does not require formal PMDA approval review. |
|
Ninsho — Certification |
Eligible Class II and designated Class III devices |
No single PMDA timeline |
A Registered Certification Body reviews the application. |
|
Shonin — New Device |
New or higher-risk devices requiring formal approval |
Approx. 12 months |
PMDA review and MHLW approval apply. |
|
Shonin — Generic Device |
Devices substantially equivalent to an approved product |
Approx. 4 months |
Equivalence evidence supports the shorter review route. |
For context, PMDA reported 11.7 months for standard new-device applications in FY2024, close to the 12-month indicative benchmark.
Final Words
Japan’s oversight increasingly reaches overseas manufacturing sites. In FY2024, PMDA processed 32 on-site QMS inspection cases for foreign medical device facilities. Therefore, medical device registration in Japan should begin with inspection-ready quality systems, controlled documentation, and clear manufacturing-site responsibilities—not only a complete submission file.
Medical Devices & IVDs EU Registration
We guide companies through medical device and IVD EU registration by supporting MDR and IVDR requirements, technical documentation, and structured processes for compliant market access.
FAQ
Yes. PMDA can conduct on-site or document-based QMS inspections of overseas registered manufacturing sites to verify compliance with Japan’s quality requirements.
Manufacturers should maintain controlled QMS records covering manufacturing, quality control, responsibilities, procedures, and evidence of compliance with QMS Ordinance 169. The documented system should also match the approved product and manufacturing arrangements.
Yes. Inconsistent manufacturing information, incomplete supporting records, or unreliable submission data can trigger regulatory questions and additional assessment before approval. Therefore, manufacturers should verify application data and site documentation before submission.
References
Alireza Zarei is the founder and CEO of Zamann Pharma Support GmbH in Germany. He pairs 20 years in GMP—beginning in a lab in 2005—with front-line global project delivery for companies such as Boehringer Ingelheim, Roche, BioNTech, Takeda, Fresenius Medical Care, Biotest, ratiopharm and others. He focuses on innovative validation and qualification procedures, master data management strategies, end-to-end LIMS implementation and care, with pragmatic advice on general Quality Management topics and management level OpEx consulting. Together with his team he also created Pharmuni.com as the leading GMP learning platform in the industry.